Replies to post #28671 on Biotech Values

[DewDiligence]

>I think the rap on ARDM is that the NovoNordisk phase II is going to take 2-3 years to enroll.<

Everyone knows that NVO/ARDM is a distant third in the inhaled-insulin arena, and this program isn’t costing ARDM any money. (NVO’s trials are phase-3, by the way.) The problems discussed on the CC have to do with the other facets of ARDM’s business.